CHENG-PING WANGYIH-LEONG CHANGTing L.-L.TSUNG-LIN YANGJENG-YUH KOPEI-JEN LOU2020-03-072020-03-0720091043-3074https://www.scopus.com/inward/record.uri?eid=2-s2.0-58149529375&doi=10.1002%2fhed.20936&partnerID=40&md5=660e8037b2a7146a5a9d2c73895ba1e0https://scholars.lib.ntu.edu.tw/handle/123456789/473852Background. Sinonasal malignant fibrous histiocytoma (MFH) is rare. Methods. Twenty-five patients were registered with a diagnosis of sinonasal MFH at our hospital in the past 30 years. Clinical data were retrospectively reviewed. Results. Eight tumors were primary MFH and 17 tumors were post-irradiated MFH, located within the radiation field for previous nasopharyngeal carcinoma. Twenty-one tumors originated from the maxillary sinus, 3 from the nasopharynx, and 1 from the nasal cavity. Twenty-three patients underwent surgery but only 12 tumors were removed completely. The 5-year overall and disease-free survival rates were 25.1% and 21.5%, respectively. Multivariate analyses showed that previous radiation was the only adverse prognostic factor for disease-free survival (p = .045). The 5-year disease-free survival rates of primary MFH and post-irradiated MFH were 72.9% and 0%. Conclusion. In this series, post-irradiated MFH was more common than primary MFH. The prognosis of post-irradiated MFH is poor, whereas primary MFH is fair. ? 2008 Wiley Periodicals, Inc.[SDGs]SDG3adolescent; adult; aged; article; cancer radiotherapy; cancer staging; cancer surgery; child; clinical article; disease free survival; female; human; male; malignant fibrous histiocytoma; maxillary sinus; nasopharynx carcinoma; nose cavity; overall survival; paranasal sinus; priority journal; prognosis; radiation dose; radiation field; retrospective study; school child; survival rate; tumor classification; Adolescent; Adult; Aged; Child; Disease-Free Survival; Female; Head and Neck Neoplasms; Histiocytoma, Malignant Fibrous; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasms, Radiation-Induced; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Young Adultjournal article10.1002/hed.20936188534462-s2.0-58149529375